POSITIONS AVAILABLE (ALL LEVELS)
NEXT GENERATION CELL AND GENE THERAPY TECHNOLOGY
Sana Biotechnology is a public cell and gene therapy company with an aspirational vision to be able to control or modify any gene in the body, to replace any cell that is damaged or missing, and to markedly improve access to cellular and gene-based medicines. The company has brought together an experienced group of scientists, engineers, and company builders and combined them with the necessary technologies to move this vision forward. In addition to Sana’s research and development efforts to progress its existing pipeline of therapeutic products, the company is committed to investing in research and other activities that will ensure a leadership position in the future, and towards that end, has established SanaX, a distinct research arm of the company. SanaX research efforts are aimed at making fundamental improvements to existing technologies and establishing new paradigms for gene and cell delivery that will ultimately lead to the development of completely new therapeutic modalities. SanaX is led by Dr Richard Mulligan, the executive vice chairman of Sana.
In the area of gene therapy, SanaX is focused on the development of both next generation and re-purposed viral vectors, including those derived from lentiviruses, adenoviruses, and adeno-associated viruses, and the development of systems for the exogenous regulation of transgene expression. In the area of cell therapy, a major focus of the team is to develop cells as gene delivery vehicles. Dr. Mulligan seeks experienced individuals at every levels to join the SanaX team. Preference will be given to candidates with a deep understanding of a relevant technology or biology. A record of creativity and productivity is essential. The position will be based at SanaX in Cambridge, Massachusetts.
If interested in learning more please contact Ray Amato @ email@example.com